DBV to start Phase II trial of peanut allergy immunotherapy
This article was originally published in Clinica
Executive Summary
French firm DBV Technologies is to begin a Phase II study of its VIASKIN Peanut product, for patients with peanut allergy, in mid-2011. The trial has just been recommended by the US Consortium of Food Allergy Research. It will be funded by a five-year grant from the US National Institutes of Health, and will take at least three years. VIASKIN Peanut is designed to desensitise people with peanut allergies by safely exposing them to the allergen through their skin without breaking the blood-skin barrier. This could avoid systemic shock, which is a concern with other desensitisation therapies, DBV says. Eventually, the product should increase the amount of peanuts that patients can consume without experiencing symptoms.